Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H